Iterative Scopes and Eli Lilly reached a partnership Feb. 11 to conduct research around how artificial intelligence can improve understanding of inflammatory bowel disease pathophysiology and target identification.
IBD research is limited by human interpretation of results. The companies will work together to develop machine learning algorithms to improve on endoscopic clinical trial endpoint assessments.
The ultimate goal is to advance the use of AI for IBD clinical trials.
Jonathan Ng, founder and CEO of Iterative Scopes, said: "This collaboration is an important boost to Iterative Scopes' efforts to take the collective learnings from the journeys of thousands of patients. Channeling this data into providing the best possible clinical decision for each and every IBD patient."